Fenofibrate in type 2 diabetes: The FIELD study

Abstract

Keywords

Get full access to this article

View all access options for this article.

References

The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.

Feher MD , Caslake M. , Foxton J. , Cox A. , Packard CJ Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395-9.

Diabetes Atherosclerosis Intervention Study Investigators. Effects of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.

Madej A. , Okopien B. , Kowalski J. et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinaemia IIB. Int J Clin Pharmacol Ther 1998;36:345-9.

Keating GM , Ormrod D. : Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002, 62:1909-44.

Turner RC , Millns H. , Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8.

Colhoun HM , Betteridge DJ , Durrington PN et al. (Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V. Fuller JH,) on behalf of the CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.

Collins R. , Armitage J. , Parish S. et al. for the Heart Protection Study Collaborative Group. MRC/BHF heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.

Rubins HB , Robins SJ , Collins D. et al. ( Fye CL , Anderson JW , Elam BM , Faas FH , Linares E. , Schaefer EJ , Schectman G. , Wilt TJ , Wittes J. ): Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density lipoprotein cholesterol Intervention Trial study group. N Engl J Med 1999;341:410-18.

10.

Davidson MH Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90:50K-60K.

11.

Elkeles RS , Diamond JR , Poulter C. et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21:641-8.

12.

Frick MH , Elo O. , Haapa K. et al. (Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V and others): Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety treatment, changes in risk factors and incidence of coronary heart disease. N Eng J Med 1987;317:1237-45.

13.

Koskinen P. , Mänttäri M. , Manninen V. , Huttunen JK , Heinonen OP , Frick MH : Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.

14.